Cortexyme is a biopharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is enrolling patients in a Phase 2/3 clinical trial of its lead small molecule in mild to moderate Alzheimer's disease.